Given its pivotal role in epilepsy and pain, Cav3.2 has emerged as a promising target for the development of anti-epileptics and analgesics.39,55 Dozens of pathological mutations, including those associated with autism, amyotrophic lateral sclerosis, hyperaldosteronism familial 4, and epilepsy, are directly linked to Cav3.2 (Supplementary information, Table S5).38,56–60 The high-resolution structures of Cav3.2 enable precise mapping of nineteen mutations located in the resolved regions. This evidence concerns the gene CACNA1H and autism.